Pfizer announced an agreement with Chinese biotechnology company Innovent Biologics valued at up to $10.5 billion, in a deal focused on co-developing and commercializing cancer treatments that Innovent has been advancing through clinical trials. The agreement represents one of the largest partnerships between a major Western pharmaceutical company and a Chinese biotech in recent years.
Innovent Biologics has built a pipeline of cancer therapies, including bispecific antibodies and other oncology assets, that attracted Pfizer’s attention as the American company looks to bolster its drug pipeline following a period of intense focus on vaccines and antiviral treatments during the pandemic years. The deal gives Pfizer access to promising cancer assets while providing Innovent with the resources and global distribution network of a large multinational partner.
The value of the deal is contingent on reaching various development and regulatory milestones, with the full $10.5 billion representing a total potential payout if the partnership achieves its most optimistic targets. Initial payments and near-term commitments represent a smaller fraction of that headline figure, as is standard in large pharmaceutical partnership agreements structured around contingent milestones.
The agreement arrives at a time when pharmaceutical companies have been competing intensely to build out oncology pipelines, a therapeutic area where patient need remains high and successful drugs command premium pricing in global markets. Partnerships with Chinese biotechs, which have developed significant scientific capacity over the past decade, have become one strategy that major companies use to access that pipeline at an earlier stage than traditional acquisition permits.
Regulatory approvals for products developed under the partnership would be needed in individual markets before they could reach patients and generate commercial revenues.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.bloomberg.com/